MELAS Syndrome Clinical Trial
Official title:
Clinical Characteristics and Prognostic Factors of Mitochondrial nt3243 A>G Mutation in Taiwan
Mitochondrial diseases are multisystem disorders that present with a wide range of clinical manifestations. Mitochondrial DNA nt3243A>G mutation is one of the most common mutations seen in mitochondrial diseases. Syndromes associated with this mutation include mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), maternally inherited diabetes and deafness (MIDD), myoclonic epilepsy with ragged red fibers (MERRF), and chronic progressive external ophthalmoplegia (CPEO). Clinical analyses of mitochondrial DNA nt3243A>G mutation from Taiwan remain scarce. The present study aims to investigate the clinical features and prognostic factors of patients with mt3243A>G mutation in Taiwan.
Patients and clinical features. The study will be carried out at National Taiwan University
hospital, a tertiary medical center in Taipei. The Medical Genetics Department at National
Taiwan University Hospital receives referral and conducts genetic testing for hospitals all
around Taiwan. We will review the medical chart of all patients with documented
mitochondrial DNA nt3243 point mutation. Demographic data, age at onset of symptoms,
clinical features (including stroke, seizure-like episode, lactic level, diabetes mellitus,
hearing impairment, myopathy, electrocardiogram abnormality, chronic progressive external
ophthalmoplegia), relevant family history, treatment, and outcome will be recorded. Full
MELAS phenotype was defined as the presence of focal central nervous system events, either
seizures, strokes, or both.
Genetic analysis. Genomic DNA was extracted from peripheral blood leukocytes using the
Puregene DNA purification kit (Gentra Systems, Minneapolis, Minnesota, USA). Polymerase
chain reaction (PCR) for mitochondrial DNA nt3243 point mutation was carried out by left
primer 5'-cggagtaatccaggtcggtt-3' and right primer 5'-ggaattgaacctctgactgt-3'. Presence of
mitochondrial DNA nt3243 A>G mutation was detected after Hae III restriction enzyme
digestion.
Heteroplasmy of mitochondrial nt3243A>G mutation was detected by real-time amplification
refractory mutation system quantitative PCR (ARMS-qPCR) assay as previously reported [19].
In brief, wild-type and mutant-target primers, each 500 nM, were added into a 10-ml PCR
reaction containing 1X KAPA SYBR® FAST ABI Prism® qPCR Master Mix (KAPABIOSYSTEMS, Cat No.
KK4603) and 4 ng of genomic DNA. Real-time PCR conditions were 2 min at 50°C, 20 seconds at
95°C, followed by 40 cycles of 15 seconds of denaturation at 95°C and 30 seconds of
annealing/extension at 62°C. Data of cross point and concentration fluorescent signal
intensity of PCR products was recorded and analyzed by ABI StepOnePlusTM Real-Time PCR
System (Applied Biosystems) and StepOne software v2.1 (Applied Biosystems). The threshold
cycle ( CT value) within the linear exponential phase was used to construct the standard
curve and to measure the original copy number of DNA template. The percentage of the mutant
mtDNA was calculated using formula as below: Heteroplasmy %= 1/(1+ 1/2△CT).
Statistical analysis. SPSS 17.0 (SPSS, Chicago, IL, USA) was used for statistical analysis.
Results were given as median and range, or mean ± 1 SD, when appropriate. Student 's t-test
was used to compare unpaired groups. Fisher's exact test was used to determine associations
between two categorical variables. Cox-regression model was used to analyze possible
prognostic factors. Inter-group differences at outcome were compared by Kaplan-Meier
estimate and log-rank test. Pearson's correlation was used to correlate heteroplasmy to age
of diagnosis. A p value < 0.05 was considered statistically significant.
;
Observational Model: Case-Only, Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01831934 -
Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)
|
Phase 4 | |
Not yet recruiting |
NCT06013397 -
Effectiveness of Ketogenic Diet in MELAS Syndrome
|
N/A | |
Completed |
NCT04165239 -
The KHENERGYZE Study
|
Phase 2 | |
Completed |
NCT01603446 -
L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome
|
Phase 2 | |
Completed |
NCT00887562 -
Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes
|
Phase 2 | |
Active, not recruiting |
NCT00068913 -
Evaluating the Effectiveness of a Dichloroacetate in MELAS Syndrome
|
Phase 2 | |
Completed |
NCT03888716 -
A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease
|
Phase 1 | |
Completed |
NCT04948138 -
Glutamine Supplement in MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes) Syndrome
|
N/A | |
Completed |
NCT03056209 -
Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT01339494 -
Nitric Oxide Production in MELAS Syndrome
|
Phase 0 | |
Active, not recruiting |
NCT05255328 -
Clinical Long Term Evaluation of Glutamine Supplement in MELAS Syndrome
|
N/A | |
Recruiting |
NCT05554835 -
Global Registry and Natural History Study for Mitochondrial Disorders
|
||
Completed |
NCT01252979 -
Ketones & Mitochondrial Heteroplasmy
|
Phase 0 | |
Completed |
NCT00004353 -
Study of the Metabolism of Pyruvate and Related Problems in Patients With Lactic Acidemia
|
N/A | |
Recruiting |
NCT03952234 -
L-Citrulline Dose Finding Safety Study in MELAS
|
Phase 1 |